GSK (GSK.L) raised its full-year profit and sales forecasts on Wednesday for the second time this year, betting on the strong launch of its respiratory syncytial virus (RSV) vaccine and steady demand for its shingles shot.
raised its full-year profit and sales forecasts on Wednesday for the second time this year, betting on the strong launch of its respiratory syncytial virus vaccine and steady demand for its shingles shot.
Analysts expect GSK's RSV vaccine Arexvy to power future growth, stemming worries about the strength of its pipeline of drugs in development and costly U.S. litigation over discontinued heartburn drug Zantac. Arexvy, launched in the United States recently, is expected to garner full-year sales of between 900 million pounds to 1 billion pounds , GSK said.
The London-listed drugmaker said it now expects a rise of 17% to 20% in annual adjusted earnings per share, excluding the effect of currency swings, up from 14%-17% growth previously forecast. It now expects sales to rise by 12% to 13% in 2023, excluding the effect of currency swings, compared with its earlier expectation of 8% to 10%.European energy companies, including Denmark's Orsted , will likely write down more of their U.S. offshore wind investments this week after BP and Equinor booked $840 million in impairments in recent days.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer RSV vaccine lags GSK’s as head-to-head competition underwayPfizer RSV vaccine lags GSK’s as head-to-head competition underway
Read more »
Pfizer RSV vaccine lags GSK’s as head-to-head competition underwayPfizer (PFE.N), which dominated COVID vaccine sales, now finds itself looking up at GSK (GSK.L), whose rival new respiratory syncytial virus (RSV) vaccine has surged to an early lead since the shots launched this summer.
Read more »
GSK Reports Earnings Wednesday. Here's What to Expect.The company will for the first time report sales of Arexvy, its new RSV vaccine that launched this fall.
Read more »
Drug Stocks Keep Falling on Earnings. It Could Be a Long Week.Companies scheduled to report their results include Pfizer, GSK, Eli Lilly, and Novo Nordisk.
Read more »
GSK signs $1 billion deal for exclusive license to J&J's hepatitis B therapyGSK signs $1 billion deal for exclusive license to J&J's hepatitis B therapy
Read more »
Cost of RSV shot raises concerns over accessibilityInsurance companies currently do not have to offer the RSV vaccine for free, placing the onus on patients and parents to cover its cost.
Read more »